REG - Abingdon Health PLC - Trading and commercial update & Directorate change

Abingdon HealthAnnouncement

15/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220815:nRSO9353Va&default-theme=true

RNS Number : 9353V  Abingdon Health PLC  15 August 2022

 

Abingdon Health plc

("Abingdon" or "the Company")

 

Trading and commercial update

& Directorate change

 

York, U.K. 15 August 2022: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality and effective rapid
tests, provides the following trading and commercial update for the year ended
30 June 2022 ("FY22").

 

FY22 Year End Trading update

The trading performance in FY22 was disappointing. FY22 revenues are expected
to be in the region of £2.8m (FY21: £11.6m (£3.6m excluding DHSC revenue
and a one off COVID customer order)) and a substantial loss for the year will
be incurred. A significant proportion of these losses relate to the increase
in operational infrastructure related to AbC-19™ and the DHSC contract and
the subsequent unwinding of this investment. As part of this, the Company
further restructured its operations early in Q4 FY22 with a reduction in
headcount from 123 employees at the end of December 2021 to 86 employees at
the end of July which, along with other cost saving measures implemented, has
significantly reduced the ongoing monthly operational cash outflow.

 

The Company's cash balance at the end of July was £7.6m, following the
settlement of the outstanding monies owed by the DHSC, including the £1.5m
that is held in a blocked account awaiting the outcome of the Judicial Review.
The Directors are of the opinion that the current cash balance gives the
Company sufficient working capital beyond the end of the current fiscal year
ending 30 June 2023 ("FY23") without material revenue growth.

 

Abingdon transitioned its focus back to its contract service business model in
FY22 and as and when the Company begins generating meaningful commercial
traction, it will look to grow its headcount sustainably and in line with the
anticipated growth of the business and revenues.

 

Technical transfer contracts

In the second half of FY22, the Company signed six new technical transfer
contracts. These commercial opportunities span a range of markets and are
underpinned by Abingdon's lateral flow expertise as well as the flexibility of
its commercial proposition. Abingdon is actively working on the transfer of
three of these projects, in the areas of fertility and food testing, with a
number of the remaining transfers anticipated to commence later in the year,
subject to various conditions being met.

 

On 17 May 2022, the Company announced that it had signed a significant
contract with a European customer with minimum revenues of £2.7m in the first
year. Due to issues unrelated to Abingdon, the technical transfer process,
which was originally expected to take two months, is yet to complete. The
Company is continuing its dialogue with the customer, however, regrettably
there is now a high degree of uncertainty around the timing or materialisation
of any revenues under this contract.

 

Following the announcement on 5 April 2022, the Company continues to work
closely with Vatic as they progress their US FDA Emergency Use Approval
("EUA") and awaits the key reagent from Vatic to begin the manufacturing of
the devices. It is anticipated that there is the potential for significant
manufacturing volume subject to Vatic attaining FDA EUA approval; although the
timing or materialisation of revenues in relation to this contract are
uncertain.

 

Abingdon Simply Test

In June 2022, Abingdon announced a supply agreement with Taiwanese group Arise
Biotech ("Arise") for the supply of 10 million Abingdon Health Simply Test
COVID-19 antigen tests, with an option for Arise to acquire an additional 20
million tests. The purchase order is subject to the Abingdon Simply Test
receiving Taiwan EUA. Abingdon continues to work closely with Arise on the
regulatory process with the Taiwanese FDA.

The Company launched its Abingdon Simply Test range on its new e-commerce site
(http://www.abingdonsimplytest.com/) on 21 July 2022, with 11 self-test
products available across a range of indications. It is intended that Abingdon
will both develop its own products and work with a range of suppliers,
including its contract service customers, to provide a broad range of
self-test products on the Abingdon Simply Test e-commerce site.

 

R&D update

Abingdon continues to develop its own self-test products and is currently
focused on two self-tests: flu and Lyme disease; both of which should reach
proof of concept shortly. The Company has also conducted some preliminary work
in the area of Hepatitis C testing.

 

In May 2022, the Company announced the signing of a strategic partnership with
DeepVerge plc for the development of a range of tests, initially focusing on
lateral flow test ("LFT") devices to detect pathogens and chemicals in
wastewater. DeepVerge will fund the development of the tests and Abingdon will
be the exclusive manufacturer following completion of the development and
technical transfer process.

 

Directorate change

Abingdon Health also announces that Mr Lyn Rees, Non-Executive Director, will
be leaving the Board of Abingdon Health at the end of September 2022. Mr Rees
is making this move due to his desire to focus on his role as CEO of Yourgene
Health plc.

 

Dr Chris Hand, Non-Executive Chairman of Abingdon Health said: "I would like
to thank Lyn for his tremendous contribution since he joined the Abingdon
Board in June 2020.  It has been a pleasure to work with Lyn and I wish him
well as he concentrates on his role at Yourgene Health plc."

 

Commenting on trading and outlook, Chris Yates, CEO of Abingdon Health plc,
said: "Despite what has been a challenging year for the Company, we are
nonetheless encouraged by our progress, with a range of new COVID-19 and
non-COVID-19 opportunities. We believe that FY23 will see a return to revenue
growth and that our programme of investment will see us begin to generate
meaningful commercial traction.

 

"FY22 was disappointing in many respects, particularly the distraction of the
Judicial Review and the challenges in resolving the lack of payment from the
DHSC. Despite this hindrance we have built a solid base of international
opportunities and we look forward to the new financial year with a growing
base of contract service customers."

 

 

Enquiries:

 

 Abingdon Health plc                                                                   www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                                  Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Dr Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)                            Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited                                      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                                          (mailto:abingdon@walbrookpr.com)
 Phillip Marriage / Alice Woodings  Mob: +44 (0)7867 984 082 / +44 (0)7407 804 654

 

 

 

 

About Abingdon Health plc

 

Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests
(https://www.abingdonhealth.com/services/)  across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial concept through
to routine and large-scale manufacturing and has also developed and marketed
its own labelled tests.

 

The Company offers product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes. This ability has a significant role to play in improving life across
the world. To support this aim Abingdon Health has also developed AppDx(®),
a customisable image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of
this announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTEAEPLFSDAEFA